B cell–depleting therapy with rituximab, which was originally developed for the treatment of rheumatoid arthritis and B cell malignancies, is an appealing therapeutic option, especially because B cells may be involved in the production of galactose-deficient IgA1 and its antibodies in IgA nephropathy. The gene discussed is IGHA1; the disease is rheumatoid arthritis.